Fulvestrant

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4445 publications

Capivasertib for locally advanced or metastatic breast cancer.

Capivasertib for locally advanced or metastatic breast cancer.

Journal: Australian prescriber

Published: June 18, 2026

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2026

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer.

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.

Using Deep Learning Models of Gene Regulation to Guide Drug Prioritization.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

Blocking estrogen receptors restores surface mGluR5 but not downstream signaling in female APP/PS1 Mice.

Blocking estrogen receptors restores surface mGluR5 but not downstream signaling in female APP/PS1 Mice.

Journal: Molecular brain

Published: April 21, 2026

Cost-effectiveness analysis of capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective.

Cost-effectiveness analysis of capivasertib plus fulvestrant in the PIK3CA/AKT1/PTEN-altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective.

Journal: Journal of medical economics

Published: April 20, 2026

Bushen Yijing formula exerts chondroprotective effects in knee osteoarthritis via the ERα/PI3K/AKT signaling pathway: Insights from network pharmacology and experimental validation.

Bushen Yijing formula exerts chondroprotective effects in knee osteoarthritis via the ERα/PI3K/AKT signaling pathway: Insights from network pharmacology and experimental validation.

Journal: Tissue & cell

Published: April 10, 2026

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Journal: JCO precision oncology

Published: April 09, 2026

Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer.

Analysis of the Frequency and Associated Factors of Skin Toxicity in Patients Receiving Ribociclib-Based Therapy for Metastatic Breast Cancer.

Journal: Cancers

Published: April 09, 2026

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Journal: ESMO real world data and digital oncology

Published: April 03, 2026

Culmerciclib: First Approval.

Culmerciclib: First Approval.

Journal: Drugs

Published: March 27, 2026

CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners.

CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: March 24, 2026

Showing 1-12 of 4,445

Last Updated: 06/30/2026